MarketCap
Facebook
X
Telegram
Inovio Pharmaceuticals Income Statement 2025-2008 | INO
Brief overview of financial results at Inovio Pharmaceuticals
This overview is based on financial performance over the past five years. Revenue reported by Inovio Pharmaceuticals was 7.4 million dollars at the beginning of the period and 65.3 thousand dollars at the end. The five-year change reached −99.1%, while CAGR stood at −61.2%. The negative rate indicates weakening core operations.
EBITDA was −$121 million at the beginning and −$85.4 million at the end of the period (+29.4%). Operating profitability strengthened faster than the scale of sales. At the operating-margin level, the figure shifted from −1633.2% to −130701.4%. The margin contraction indicates weaker operating efficiency.
Net income moved from −$166 million at the start to −$85 million at the end. The loss narrowed, although sustainable profitability has not yet returned.
Market capitalization changed from $1.7 billion to $98.5 million (−94.3%). The market is not yet fully reflecting the fundamental progress.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. The constructive conclusion rests on a stronger final result. The most visible risks are weak sales momentum, declining capitalization and pressure on operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Inovio Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
98.5 M | 276 M | 220 M | 24.5 M | 56.4 M | 1.72 B | 460 M | 466 M | 386 M | 450 M | 456 M | 493 M | 485 M | 87.4 M | 72 M | 5.85 B | - | - |
Shares |
46.9 M | 27.2 M | 22.2 M | 19.9 M | 17.4 M | 155 M | 98.7 M | 92.5 M | 81.8 M | 73.2 M | 68.2 M | 59.1 M | 46.1 M | 34.1 M | 31.6 M | 103 M | - | - |
Historical Prices |
2.1 | 10.2 | 9.93 | 1.23 | 3.24 | 11.1 | 4.28 | 3.66 | 4.1 | 7.05 | 6.3 | 7.08 | 13.2 | 2.76 | 2.32 | 56.6 | 30.2 | 37.4 |
Net Income |
-85 M | -107 M | -135 M | -280 M | -304 M | -166 M | -119 M | -97 M | -88.2 M | -73.7 M | -29.2 M | -36.1 M | -66 M | -19.7 M | -15.3 M | -17.6 M | -24.4 M | - |
Revenue |
65.3 K | 218 K | 832 K | 10.3 M | 1.77 M | 7.41 M | 4.11 M | 30.5 M | 42.2 M | 35.4 M | 40.6 M | 10.5 M | 13.5 M | 4.12 M | 9.8 M | 6.14 M | 9.12 M | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 40.6 M | 10.5 M | 13.5 M | 4.12 M | 9.8 M | - | - | - |
Operating Income |
-86.8 M | -112 M | -144 M | -268 M | -301 M | -124 M | -111 M | -94.1 M | -83.6 M | -76.2 M | -34.3 M | -39.5 M | -19.5 M | -23.5 M | -21.6 M | -19.2 M | -14 M | - |
Interest Expense |
-2.64 M | -3.16 M | 1.22 M | 1.25 M | 1.94 M | 8.7 M | 7.95 M | - | 25.9 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-85.4 M | -111 M | -141 M | -264 M | -298 M | -121 M | -106 M | -89.1 M | -81.2 M | -74.1 M | -33.4 M | -37.9 M | -19.4 M | -22.6 M | -20.2 M | -19 M | -13.7 M | - |
Operating Expenses |
86.9 M | 113 M | 145 M | 278 M | 303 M | 131 M | 115 M | 125 M | 127 M | 113 M | 75.9 M | 50 M | 35 M | 28.8 M | 32 M | 25.4 M | 23.1 M | - |
General and Administrative Expenses |
32.7 M | 37 M | 47.6 M | 90.2 M | 53.8 M | 37.2 M | 27.2 M | 29.3 M | 28.3 M | 23.9 M | 18.1 M | 15.9 M | 13.6 M | 10.8 M | 12 M | 12.1 M | 13.7 M | - |
All numbers in USD currency
Quarterly Income Statement Inovio Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
69.1 M | 52.2 M | 38.8 M | 38.6 M | 36.1 M | 28.1 M | 27.2 M | 23.3 M | 22.8 M | 22.4 M | 22 M | 21.5 M | 253 M | 249 M | 235 M | 219 M | 217 M | 210 M | 210 M | 202 M | 187 M | 165 M | 156 M | 125 M | 101 M | 99 M | 98.1 M | 97.5 M | 97.2 M | 92.4 M | 91.2 M | 90.5 M | 90.4 M | 87 M | 75.4 M | 74.2 M | 74.1 M | 73.6 M | 73 M | 72.2 M | 72.2 M | 72 M | 67.7 M | 60.7 M | 60.6 M | 60.4 M | 60.2 M | 55.2 M | 52.1 M | 48 M | 45 M | 39 M | 141 M | 135 M | 135 M | 135 M | 129 M | 127 M | 127 M | 121 M |
Net Income |
-19.7 M | -45.5 M | -23.5 M | -19.7 M | - | -25.2 M | -32.2 M | -30.5 M | - | -33.9 M | -35.5 M | -40.6 M | - | -37.8 M | -108 M | -79.1 M | - | -60.2 M | -82.1 M | -54.4 M | -24.3 M | 19.2 M | -129 M | -32.5 M | -37.7 M | -23.1 M | -29.4 M | -29.2 M | -33 M | -25 M | -6.64 M | -32.4 M | -21.5 M | -34.1 M | -9.48 M | -23.1 M | -26.2 M | -20.8 M | -18.7 M | -8.04 M | -18 M | 5.59 M | -6.25 M | -10.6 M | -7.41 M | -7.18 M | -10.7 M | -10.8 M | -15.5 M | -30.9 M | -10.9 M | -8.84 M | -659 K | -6.62 M | -4.13 M | -8.25 M | -5.48 M | -4.54 M | -2.82 M | -2.41 M |
Revenue |
- | - | - | 65.3 K | - | - | 101 K | - | - | 388 K | 226 K | 115 K | - | 9.15 M | 784 K | 199 K | - | 292 K | 273 K | 769 K | 931 K | 897 K | 1.07 M | 417 K | 588 K | 637 K | 755 K | 626 K | 2.5 M | 565 K | 519 K | 1.53 M | 8.79 M | 2.64 M | 20.4 M | 10.4 M | 8.51 M | 12.5 M | 6.2 M | 8.11 M | 5.94 M | 24.2 M | 5.29 M | 5.17 M | 2.46 M | 1.84 M | 3.8 M | 2.36 M | 1.74 M | 9.49 M | 786 K | 1.46 M | 1.13 M | 855 K | 436 K | 1.69 M | 1.63 M | 2.64 M | 2.42 M | 3.11 M |
Operating Income |
-21.9 M | -21.2 M | -23.1 M | -25.1 M | - | -27.3 M | -33.2 M | -31.5 M | - | -35.6 M | -37 M | -44 M | - | -35.8 M | -104 M | -71.7 M | - | -60 M | -83.2 M | -52.6 M | -29.3 M | -36.3 M | -33.2 M | -25.2 M | -30.4 M | -24 M | -28.2 M | -28.5 M | -29.5 M | -26.6 M | -5.2 M | -32.7 M | -22.9 M | -29.2 M | -9.64 M | -21.9 M | -22.4 M | -20.2 M | -18.2 M | -15.5 M | -14.5 M | 3.73 M | -15.1 M | -8.37 M | -11 M | -8.33 M | -10.2 M | -10 M | -8 M | 766 K | -5.67 M | -6.63 M | -6.23 M | -6.29 M | -6.79 M | -4.19 M | -5.78 M | -6.34 M | -5.14 M | -4.39 M |
Interest Expense |
-285 K | -1.94 M | -703 K | -482 | - | -580 K | 7.57 K | -682 K | - | 2.85 K | -1.43 M | 313 K | - | 313 K | 313 K | 313 K | - | 476 K | 467 K | 513 K | 1.07 M | 1.98 M | 2.85 M | 2.8 M | 2.67 M | 2.43 M | 2.19 M | 656 K | -169 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 347 K | 4.9 M | - |
EBITDA |
-21.6 M | - | - | -24.7 M | - | - | - | -31.1 M | - | - | - | -43.2 M | - | -33 M | -102 M | -70.8 M | - | -57.9 M | -81.8 M | -51.9 M | -29.3 M | -34 M | -31.6 M | -24.4 M | -30.4 M | -21.2 M | -26.3 M | -27.6 M | -29.5 M | -23.9 M | -3.36 M | -31.8 M | -22.9 M | -27.4 M | -8.62 M | -21.4 M | -22.4 M | -18.9 M | -17.4 M | -15.1 M | -14.5 M | 4.46 M | -14.7 M | -8.15 M | -11 M | -7.9 M | -9.91 M | -9.88 M | -8 M | 890 K | -5.59 M | -6.59 M | -6.23 M | -6.17 M | -6.71 M | -4.15 M | -5.78 M | -6.23 M | -5.07 M | -4.35 M |
Operating Expenses |
21.9 M | 21.2 M | 23.1 M | 25.1 M | - | 27.3 M | 33.3 M | 31.5 M | - | 35.9 M | 37.3 M | 44.1 M | - | 44.9 M | 105 M | 71.9 M | - | 60.2 M | 83.5 M | 52.9 M | 34.9 M | 36.6 M | 33.4 M | 26.6 M | 30.7 M | 24.8 M | 28.3 M | 31.4 M | 32 M | 28.6 M | 29.7 M | 34.3 M | 31.7 M | 31.8 M | 30 M | 32.3 M | 30.9 M | 32.7 M | 24.4 M | 23.6 M | 20.5 M | 20.5 M | 20.4 M | 13.5 M | 13.5 M | 10.2 M | 14 M | 12.4 M | 9.74 M | 8.72 M | 6.46 M | 8.09 M | 7.36 M | 7.15 M | 7.22 M | 5.88 M | 7.41 M | 8.97 M | 7.56 M | 7.49 M |
General and Administrative Expenses |
7.88 M | 7.88 M | 8.56 M | 9.02 M | - | 8.61 M | 10.2 M | 10.6 M | - | 9.93 M | 13.5 M | 13.9 M | - | 11.8 M | 48.5 M | 16 M | - | 13.2 M | 12.7 M | 13.9 M | 8.62 M | 10.1 M | 11.1 M | 7.45 M | 8.7 M | 5.68 M | 5.85 M | 6.98 M | 5.64 M | 6.79 M | 7.19 M | 9.7 M | 8.03 M | 6.32 M | 6.17 M | 7.77 M | 6.97 M | 5.76 M | 5.8 M | 5.37 M | 4.86 M | 4.38 M | 4.72 M | 4.11 M | 4.22 M | 3.15 M | 4.35 M | 4.13 M | 4.34 M | 3.28 M | 3.05 M | 2.97 M | 2.92 M | 2.67 M | 2.7 M | 2.49 M | 3.25 M | 2.32 M | 3.09 M | 3.32 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Inovio Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
